EF
UTHR icon

Entrust Financial’s United Therapeutics UTHR Stock Holding History

Entrust Financial’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.4K Sell
34
-14
-29% -$7.88K 0.01% 249
2026
Q1 		$28.5K Sell
48
-15
-24% -$7.47K 0.02% 184
2025
Q4 		$30.7K Buy
+63
New +$29.3K 0.02% 186

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Entrust Financial's UTHR Position: Q2 2026 in Review

Entrust Financial reduced its United Therapeutics (UTHR) stake by 29% in Q2 2026, selling an estimated $7.88K and leaving 34 shares worth $18.4K. The position accounts for 0.01% of the portfolio, ranked #249.

Entrust Financial first reported a position in UTHR in Q4 2025 and has held it in 3 quarters since. The position peaked at $30.7K in Q4 2025. 875 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Entrust Financial held 34 shares of United Therapeutics worth $18.4K as of Q2 2026.
  • Entrust Financial sold 14 United Therapeutics shares in Q2 2026, an estimated $7.88K.
  • United Therapeutics made up 0.01% of Entrust Financial's portfolio in Q2 2026, its #249 holding.
  • Entrust Financial first reported a position in United Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Entrust Financial's United Therapeutics position peaked at $30.7K in Q4 2025.
  • 875 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Entrust Financial's 13F filing for Q2 2026, filed 20 Jul 2026.